Search

Your search keyword '"Psoriatic arthritis -- Care and treatment"' showing total 26 results
Start Over Descriptor "Psoriatic arthritis -- Care and treatment" Publisher syndigate media inc.
26 results on '"Psoriatic arthritis -- Care and treatment"'

1. MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Subjects
Psoriatic arthritis -- Care and treatment, Adalimumab, Telecommunications industry
Abstract

(GlobeNewswire) - MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the [...]

Published
2024

2. AbbVie's Skyrizi expands insurance benefits for adult psoriatic arthritis

Subjects
AbbVie Korea, Psoriatic arthritis -- Care and treatment, Food -- Safety and security measures, Antiarthritic agents, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Dermatologic agents, Pharmaceutical industry, Banking, finance and accounting industries
Abstract

AbbVie Korea said on Tuesday that its psoriasis drug Skyrizi (ingredient: risankizumab) will be reimbursed as a treatment from March 1, for active and progressive psoriatic arthritis in adult patients [...]

Published
2023

3. United States : New Late-Breaking Results from Phase 3 Trials of SKYRIZI (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100

Subjects
Psoriatic arthritis -- Care and treatment, Antiarthritic agents -- Evaluation -- Product development, Skin -- Analysis, Business, international
Abstract

- Analyses included 100-week efficacy and safety data from the four-year, open-label extension period of KEEPsAKE 1 and 2 evaluating SKYRIZI in patients with active psoriatic arthritis1 - Ongoing treatment [...]

Published
2022

4. United States : A Newly Published Network Meta-Analysis (NMA) Found TREMFYA (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies

Subjects
Johnson & Johnson -- Rankings, Psoriatic arthritis -- Care and treatment, Skin, Pharmaceutical industry -- Rankings, Business, international, Tremfya (Medication) -- Rankings
Abstract

The NMA indirectly compared all published Phase 3 data for approved treatments for adults with active PsA TREMFYA ranked highest among 23 active PsA treatment regimens on skin clearance (PASI [...]

Published
2022

5. United States : AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis

Subjects
Psoriatic arthritis -- Care and treatment, Antiarthritic agents, Drug approval, Adults, Business, international, European Union, European Union. European Commission
Abstract

AbbVie today announced that the European Commission (EC) has approved SKYRIZI (risankizumab, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination [...]

Published
2021

6. United States : New Comprehensive Phase 3 Data Show First-in-Class TREMFYA (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years

Subjects
Johnson & Johnson -- Product development, Psoriatic arthritis -- Care and treatment, Medical research, Medicine, Experimental, Clinical trials, Pharmaceutical industry -- Product development, Business, international, Tremfya (Medication) -- Product development
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER2 trial of TREMFYA (guselkumab) were published in Arthritis & Rheumatology, representing the [...]

Published
2021

7. United States : AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)

Subjects
Psoriatic arthritis -- Care and treatment, Antirheumatic agents, Drug approval, Adults, Business, international, European Union, European Union. European Commission
Abstract

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (SKYRIZI, 150 mg, subcutaneous injection at week 0, week [...]

Published
2021

10. CHMP Recommends the Approvals of RINVOQ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis

Subjects
Clinical trials, Ankylosing spondylitis -- Care and treatment, Medical research, Psoriatic arthritis -- Care and treatment, Antiarthritic agents, Adults, Business, international, Law, Rinvoq (Medication)
Abstract

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ (upadacitinib, 15 mg), an oral, once [...]

Published
2020

11. Janssen's Tremfya approved for active psoriatic arthritis

Subjects
Guselkumab, Psoriatic arthritis -- Care and treatment, Drug approval, Antiarthritic agents, Business, international, Law, Tremfya (Medication)
Abstract

The European Commission has approved Janssens Tremfya (guselkumab) as a first-in-class treatment for active psoriatic arthritis (PsA). The decision allows doctors to prescribe the drug for adults with active psoriatic [...]

Published
2020

12. Novartis Cosentyx shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study

Subjects
Novartis AG, Secukinumab, Pharmaceutical industry, Psoriatic arthritis -- Care and treatment, Synovitis -- Care and treatment, Business, international, Law, American College of Rheumatology, Cosentyx (Medication)
Abstract

Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which demonstrated the significant treatment response of Cosentyx (secukinumab) on [...]

Published
2020

13. MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)

Subjects
MorphoSys AG, Guselkumab, Biotechnology industries, Psoriatic arthritis -- Care and treatment, Biological products industry, Antiarthritic agents, Adults, Business, international, Law, European Union, Tremfya (Medication)
Abstract

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC. (Janssen) has announced it received a positive opinion [...]

Published
2020

14. AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ(TM) (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

Subjects
United States. Food and Drug Administration -- Technology application, Psoriatic arthritis -- Care and treatment, Adalimumab -- Technology application, Adults -- Technology application, Respiratory system agents, Skin, Arthritis, Antiarthritic agents, Chairpersons, Psoriasis, Diseases, Technology application, Business, international, Law
Abstract

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines [...]

Published
2020

15. Janssen announces submission of two applications to US FDA seeking approval of SIMPONI ARIA to treat polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis

Subjects
United States. Food and Drug Administration -- Technology application, Johnson & Johnson -- Technology application, Tumor necrosis factor -- Technology application, Methotrexate -- Technology application, Golimumab -- Technology application, Psoriatic arthritis -- Care and treatment, Drug approval -- Technology application, Pharmaceutical industry -- Technology application, Respiratory system agents, Arthritis, Antiarthritic agents, Necrosis, Tumors, Psoriasis, Technology application, Business, international, Law, Simponi (Medication)
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI [...]

Published
2020

16. Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Subjects
United States. Food and Drug Administration -- Technology application, Johnson & Johnson -- Technology application, Tumor necrosis factor -- Technology application, Golimumab -- Technology application, Psoriatic arthritis -- Care and treatment, Drug approval -- Technology application, Pharmaceutical industry -- Technology application, Respiratory system agents, Arthritis, Antiarthritic agents, Necrosis, Methotrexate, Tumors, Psoriasis, Technology application, Business, international, Law, Simponi (Medication)
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of [...]

Published
2020

17. United States : First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate

Subjects
Tumor necrosis factor, Methotrexate, Psoriatic arthritis -- Care and treatment, Etanercept, Business, international, American College of Rheumatology, Enbrel (Medication)
Abstract

Amgen announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel (etanercept) monotherapy and ENBREL plus methotrexate to methotrexate monotherapy in patients with psoriatic arthritis [...]

Published
2018

18. Switzerland : Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis

Subjects
Novartis AG, Ankylosing spondylitis -- Care and treatment, Pharmaceutical industry, Psoriatic arthritis -- Care and treatment, Business, international, Cosentyx (Medication)
Abstract

Novartis, a leader in immuno-dermatology and rheumatology, announced it will be presenting five-year data from the ongoing extensions of the phase III FUTURE 1 and MEASURE 1 studies for Cosentyx [...]

Published
2018

19. Lillys Taltz cleared to treat psoriatic arthritis

Subjects
Antirheumatic agents, Dermatologic agents, Psoriatic arthritis -- Care and treatment, Business, international, Taltz (Medication)
Abstract

US regulators have expanded the scope of Eli Lillys plaque psoriasis drug Taltz to include the treatment patients with psoriatic arthritis. Taltz (ixekizumab) is an antibody that binds to interleukin-17A, [...]

Published
2017

20. United States : New Phase 2 Data Show Treatment With Tremfya (Guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year

Subjects
Monoclonal antibodies, Psoriatic arthritis -- Care and treatment, Business, international, Tremfya (Medication) -- Product development
Abstract

Janssen Research & Development, LLC (Janssen) announced today longer-term results from a Phase 2 study investigating TREMFYA (guselkumab), the first selective anti-interleukin (IL)-23 monoclonal antibody to show positive results in [...]

Published
2017

21. United States : New Phase 2 Data Show Treatment With TREMFYA (Guselkumab) Improved Psoriatic Arthritis Symptoms Through One year

Subjects
Monoclonal antibodies, Psoriatic arthritis -- Care and treatment, Business, international, Tremfya (Medication) -- Product development
Abstract

Janssen Research & Development, LLC (Janssen) announced today longer-term results from a Phase 2 study investigating TREMFYA (guselkumab), the first selective anti-interleukin (IL)-23 monoclonal antibody to show positive results in [...]

Published
2017

22. United States : New Phase 3 Data Show Anti-TNF Alpha SIMPONI ARIA (golimumab) Significantly Improved Arthritis And Skin Manifestations In Patients With Active Psoriatic Arthritis

Subjects
Tumor necrosis factor, Skin, Psoriatic arthritis -- Care and treatment, Business, international, Simponi (Medication) -- Product development
Abstract

Janssen Research & Development, LLC (Janssen) announced today results from the pivotal Phase 3 GO-VIBRANT study that showed the significant efficacy of the intravenously administered anti-tumor necrosis factor (TNF)-alpha therapy [...]

Published
2017

23. Spain : New Phase 3 Data show Anti-TNF Alpha Simponi Aria (golimumab) Significantly Improved Arthritis and Skin Manifestations In Patients With Active Psoriatic Arthritis

Subjects
Tumor necrosis factor, Skin, Psoriatic arthritis -- Care and treatment, Business, international, Simponi (Medication) -- Product development
Abstract

Janssen Research & Development, LLC (Janssen) announced today results from the pivotal Phase 3 GO-VIBRANT study that showed the significant efficacy of the intravenously administered anti-tumor necrosis factor (TNF)-alpha therapy [...]

Published
2017

24. Switzerland : Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis

Subjects
Novartis Pharma AG, Ankylosing spondylitis -- Care and treatment, Pharmaceutical industry, Psoriatic arthritis -- Care and treatment, Business, international, European Union. European Commission, Cosentyx (Medication)
Abstract

Novartis announced today that the European Commission (EC) has approved Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is [...]

Published
2015

25. Switzerland : Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis

Subjects
Novartis Pharma AG, Ankylosing spondylitis -- Care and treatment, Anti-inflammatory agents, Pharmaceutical industry, Psoriatic arthritis -- Care and treatment, Business, international, Cosentyx (Medication)
Abstract

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx(TM) (secukinumab) in Europe to treat ankylosing spondylitis (AS) and psoriatic arthritis [...]

Published
2015

26. Switzerland : Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients

Subjects
Psoriatic arthritis -- Care and treatment, Business, international, American College of Rheumatology
Abstract

Novartis announced today first ever results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies showing AIN457 (secukinumab) demonstrated rapid and significant clinical improvements versus placebo in improving [...]

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results